AbbVie Ownership
| ABBV Stock | USD 213.85 0.62 0.29% |
Shares in Circulation | First Issued 2011-03-31 | Previous Quarter 1.8 B | Current Value 1.8 B | Avarage Shares Outstanding 1.6 B | Quarterly Volatility 97.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
AbbVie |
AbbVie Stock Ownership Analysis
About 74.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.45. AbbVie Inc last dividend was issued on the 15th of April 2025. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 50000 people. For more info on AbbVie Inc please contact Robert CPA at 847 932 7900 or go to https://www.abbvie.com.Besides selling stocks to institutional investors, AbbVie also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AbbVie's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AbbVie's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AbbVie Quarterly Liabilities And Stockholders Equity |
|
AbbVie Insider Trades History
Less than 1% of AbbVie Inc are currently held by insiders. Unlike AbbVie's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AbbVie's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AbbVie's insider trades
AbbVie Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AbbVie is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AbbVie Inc backward and forwards among themselves. AbbVie's institutional investor refers to the entity that pools money to purchase AbbVie's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-12-31 | 21.8 M | Fmr Inc | 2024-12-31 | 18.1 M | Franklin Resources Inc | 2024-12-31 | 17.2 M | Capital World Investors | 2024-12-31 | 16.4 M | Bank Of New York Mellon Corp | 2024-12-31 | 13.7 M | Ameriprise Financial Inc | 2024-12-31 | 13 M | Ubs Group Ag | 2024-12-31 | 12.6 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 12.1 M | Legal & General Group Plc | 2024-12-31 | 11.6 M | Vanguard Group Inc | 2024-12-31 | 173.1 M | Blackrock Inc | 2024-12-31 | 142 M |
AbbVie Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AbbVie insiders, such as employees or executives, is commonly permitted as long as it does not rely on AbbVie's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AbbVie insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richard Gonzalez over two months ago Disposition of 87050 shares by Richard Gonzalez of AbbVie at 61.36 subject to Rule 16b-3 | ||
Timothy Richmond over three months ago Disposition of 30288 shares by Timothy Richmond of AbbVie at 177.71 subject to Rule 16b-3 | ||
Robert Alpern over six months ago Acquisition by Robert Alpern of tradable shares of AbbVie at 171.52 subject to Rule 16b-3 | ||
Edward Rapp over six months ago Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 | ||
Carrie Strom over a year ago Payment of 2876 shares by Carrie Strom of AbbVie subject to Rule 16b-3 |
AbbVie's latest congressional trading
Congressional trading in companies like AbbVie Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AbbVie by those in governmental positions are based on the same information available to the general public.
| 2025-02-11 | Representative Jared Moskowitz | Acquired Under $15K | Verify | ||
| 2025-01-07 | Representative Virginia Foxx | Acquired Under $15K | Verify | ||
| 2024-11-22 | Representative Marjorie Taylor Greene | Acquired Under $15K | Verify | ||
| 2024-09-06 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-08-16 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-02-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-02-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-12-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-09-05 | Representative Michael C Burgess | Acquired $15K to $50K | Verify | ||
| 2023-07-18 | Representative Michael C Burgess | Acquired $15K to $50K | Verify | ||
| 2022-08-19 | Representative Dwight Evans | Acquired Under $15K | Verify | ||
| 2021-12-21 | Representative Adam B Schiff | Acquired $15K to $50K | Verify | ||
| 2021-07-30 | Representative Adam B Schiff | Acquired Under $15K | Verify | ||
| 2021-07-28 | Representative Steve Chabot | Acquired Under $15K | Verify | ||
| 2021-06-29 | Representative Debbie Dingell | Acquired $50K to $100K | Verify | ||
| 2020-10-24 | Representative Debbie Dingell | Acquired $15K to $50K | Verify | ||
| 2020-03-09 | Representative Robert J Wittman | Acquired Under $15K | Verify | ||
| 2019-09-11 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
| 2019-02-15 | Representative Van Taylor | Acquired Under $15K | Verify | ||
| 2018-10-09 | Representative Gary Palmer | Acquired Under $15K | Verify | ||
| 2018-09-29 | Representative Gary Palmer | Acquired Under $15K | Verify | ||
| 2018-08-20 | Representative John Rutherford | Acquired Under $15K | Verify | ||
| 2015-03-17 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2015-03-16 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
| 2015-03-03 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2015-03-02 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2014-04-23 | Senator John Hoeven | Acquired $50K to $100K | Verify |
AbbVie Outstanding Bonds
AbbVie issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AbbVie Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AbbVie bonds can be classified according to their maturity, which is the date when AbbVie Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ABBOTT LABS 295 Corp BondUS002824BB55 | View | |
| ABBOTT LABS 6 Corp BondUS002824AV29 | View | |
| ABBOTT LABS 53 Corp BondUS002824AY67 | View | |
| US002824BP42 Corp BondUS002824BP42 | View | |
| US002824BQ25 Corp BondUS002824BQ25 | View | |
| ABBOTT LABS 475 Corp BondUS002824BG43 | View | |
| US002824BF69 Corp BondUS002824BF69 | View | |
| ABBOTT LABS 49 Corp BondUS002824BH26 | View |
AbbVie Corporate Filings
F3 | 10th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of February 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.